Retatrutide Mechanism of Action

Introduction

Retatrutide (LY3437943) is an investigational acylated synthetic peptide classified in the peer-reviewed literature as a simultaneous agonist at three distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). A defining pharmacological feature reported by Coskun, Urva, Roell, and colleagues (2022) is retatrutide's substantially higher agonist potency at GIPR compared with native GIP itself — a characteristic that distinguishes it within the incretin agonist class [1]. This article summarizes the reported receptor pharmacology and proposed intracellular signaling mechanisms of retatrutide, drawing on published primary literature including the 2024 cryo-electron microscopy structural characterization. It does not draw independent conclusions about clinical utility or therapeutic outcomes.

Receptor Targets and Pharmacological Profile

GIP Receptor (GIPR)

The GIPR is a class B1 G protein-coupled receptor expressed in pancreatic beta cells, adipose tissue, bone, and other peripheral organs. Endogenous GIP, secreted by K cells of the small intestinal mucosa in response to nutrient intake, acts at GIPR to potentiate glucose-dependent insulin secretion.

Coskun and colleagues reported that retatrutide demonstrated substantially higher agonist potency at the GIPR compared with native GIP in cell-based assay systems [1]. This supraphysiological potency at GIPR — the dominant receptor engagement among the three targets in the molecule's in vitro profile — is described in the primary literature as a distinguishing design feature. The cryo-electron microscopy study by Li, Zhou, Cong, and colleagues (2024) subsequently characterized the residue-level molecular contacts underlying this potency profile at atomic resolution [2].

GLP-1 Receptor (GLP-1R)

The GLP-1R is a class B1 G protein-coupled receptor expressed primarily in pancreatic beta cells, the gastrointestinal tract, the central nervous system, and cardiac tissue. Endogenous GLP-1, secreted by L cells of the distal small intestine and colon in response to nutrient ingestion, stimulates glucose-dependent insulin secretion, inhibits glucagon secretion from pancreatic alpha cells, slows gastric emptying, and acts at hypothalamic and brainstem receptors to modulate satiety signaling.

Coskun et al. (2022) reported that retatrutide displayed agonist activity at GLP-1R at lower relative potency compared with native GLP-1, in contrast to its supraphysiological potency at GIPR [1]. The structural study by Li and colleagues (2024) identified the binding geometry and contact residues governing GLP-1R engagement, providing molecular context for the observed potency asymmetry across the three receptor targets [2].

Glucagon Receptor (GCGR)

The GCGR is a class B1 G protein-coupled receptor expressed predominantly in hepatocytes, with additional expression in kidney, adipose tissue, the central nervous system, and pancreatic alpha cells. Endogenous glucagon, secreted by islet alpha cells in response to hypoglycemia and prolonged fasting, acts at GCGR to stimulate hepatic glucose output via glycogenolysis and gluconeogenesis. Glucagon signaling has also been reported to affect energy expenditure through peripheral and central mechanisms.

Coskun et al. (2022) reported that retatrutide displayed agonist activity at GCGR at lower relative potency compared with native glucagon [1]. In preclinical rodent models, the authors observed that GCGR agonism contributed to body weight reductions in a manner additive to GIPR- and GLP-1R-mediated effects, and proposed that GCGR engagement contributed via increased energy expenditure as a distinct mechanism from reduced food intake alone. The Li et al. (2024) structural data characterized the distinct binding geometry retatrutide adopts at the GCGR–Gs complex and identified the molecular determinants governing this receptor interaction [2].

Reported Molecular Interactions

Structural Basis of Triple Receptor Engagement

Li, Zhou, Cong, and colleagues published cryo-electron microscopy structures of retatrutide in complex with each of the three receptor–G protein complexes (GLP-1R–Gs, GIPR–Gs, and GCGR–Gs) in Cell Discovery in 2024 [2]. The structural data characterized retatrutide's binding modes at each receptor individually. The authors reported that retatrutide adopted distinct engagement geometries at each receptor complex, with differential contact residue patterns accounting for the observed potency asymmetry across the three targets. This atomic-level characterization extended the structural understanding of multi-receptor incretin agonism to the triple-receptor context and provided a molecular framework for interpreting the compound's in vitro pharmacological profile.

Intracellular Signaling: cAMP Pathway

Agonism at GIPR, GLP-1R, and GCGR is primarily coupled to the Gs protein subunit, leading to activation of adenylyl cyclase and generation of intracellular cyclic AMP (cAMP). In pancreatic beta cells, elevated cAMP activates protein kinase A (PKA) and exchange proteins activated by cAMP (EPAC), which in turn phosphorylate downstream targets involved in insulin granule exocytosis. The glucose-dependence of this insulin secretory effect — shared with endogenous incretins — means that receptor agonism at GIPR and GLP-1R potentiates insulin release only in the presence of elevated blood glucose, a pharmacological property reported to be associated with a lower intrinsic risk of hypoglycemia relative to insulin secretagogues acting through glucose-independent mechanisms.

In hepatocytes, GCGR-coupled cAMP signaling activates PKA-dependent phosphorylation cascades governing glycogenolytic and gluconeogenic enzyme activity. The net interaction of glucagon receptor activation with concurrent incretin-driven insulin secretion has been characterized in preclinical models; the quantitative contributions of each receptor in human physiological contexts represent an ongoing area of investigation.

Downstream Effects Reported in Published Research

Preclinical Metabolic Effects

Coskun et al. (2022) reported findings from diet-induced obese rodent models in which LY3437943 administration was associated with reductions in body weight and improvements in glycemic control markers [1]. Body weight reductions observed with LY3437943 exceeded those observed with a selective GLP-1R agonist at doses producing comparable GLP-1R engagement. The authors proposed that GCGR-mediated energy expenditure contributed to this additional effect. Prior published literature supported this rationale: Johnson and colleagues (2019) reported in a mouse model that glucagon's metabolic effects on energy expenditure involve both central and multiple peripheral receptor populations, including but not limited to brown adipose tissue GCGR [3].

Reported Phase 1 Clinical Pharmacodynamics

In the phase 1b multiple-ascending-dose study in adults with type 2 diabetes reported by Urva, Coskun, Loh, and colleagues in The Lancet (2022), retatrutide administration was associated with dose-dependent changes in pharmacodynamic markers of incretin receptor engagement over the 12-week treatment period [4]. The study characterized the compound's pharmacokinetic profile and reported that it was consistent with extended-interval dosing, attributable to the albumin-binding fatty acid modification. The pharmacodynamic findings were described as consistent with engagement of the triple receptor targets.

Areas of Ongoing Investigation

Several areas of retatrutide's mechanistic pharmacology represent active research frontiers in the published literature:

The relative contribution of each of the three receptor targets to the pharmacodynamic effects observed in clinical studies continues to be characterized. Preclinical studies employ receptor-selective antagonists or knockout models to dissect receptor contributions; comparable pharmacological dissection studies in humans have been identified in the clinical trial literature as a priority for future work.

The signaling bias profile of retatrutide at GLP-1R — specifically whether it shares the preferential cAMP-over-beta-arrestin profile reported for tirzepatide by Willard et al. (2020) — represents an open question in the molecular pharmacology literature, and one that additional structural and functional studies are positioned to address.

The mechanistic basis by which GCGR agonism contributes to the body weight-related observations in clinical trials — whether via hepatic glucose regulation, energy expenditure in peripheral tissues, central nervous system signaling, or a combination — is the subject of active preclinical and translational research. The glucagon receptor's expression across multiple tissue types and its integration with incretin signals represents a scientifically rich area for future mechanistic investigation.

Long-term receptor desensitization and tolerance phenomena for the GCGR component in the context of chronic retatrutide administration are among the questions that extended phase 3 clinical trial data will help to address. A summary of the published clinical study findings is available in the retatrutide published research article. Research-grade retatrutide from SpartaLabs is supplied with third-party-verified analytical documentation.

References

1. Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. DOI: 10.1016/j.cmet.2022.07.013

2. Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov. 2024;10:77. PMID: 39019866. DOI: 10.1038/s41421-024-00700-0

3. Johnson EC, Ding EL, Bhatta A, Simcox J, Grunwald M, Bheda P, et al. The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice. Mol Metab. 2019;22:84-90. PMID: 30803918. DOI: 10.1016/j.molmet.2019.01.018

4. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. DOI: 10.1016/S0140-6736(22)02033-5